Doximity Inc. (DOCS)
NYSE NYSE Primary 
XSTU 
This Health Care Software Firm Nears Buy Point After Whopping 101% Year-To-Date Gain
Doximity stock jumped over 34% following its most recent earnings report on Nov. 11. Now, shares are nearing a buy point.
Doximity initiated with an Equal Weight at Stephens
Stephens initiated coverage of Doximity with an Equal Weight rating and $55 price target. Doximity runs the "leading digital platform for doctors" and is executing on multiple avenues of growth, though it has "settled into a low-to-mid-teens growth profile," the analyst tells investors. The firm believes the current valuation presumes revenue growth will re-accelerate based on the self-serve marketplace increasing up-sell/cross-sell and new product successes and while it sees potential for EBITDA outperformance, the firm lacks "the visibility and conviction to model above-consensus growth and further margin expansion" as a base case, the analyst tells investors.
Prescription for Profits: 3 Must-Buy Healthcare Stocks Before 2025
The healthcare sector is undergoing significant changes, with technology, innovation and a patient-centric approach as the cornerstones of its growth.
Doximity: Strong Fundamentals And Growth Potential Makes It Attractive
Doximity's dominance in digital healthcare is evident with over 80% of U.S. doctors using the platform, driving strong network effects and competitive positioning. The company boasts impressive financials, with earnings surpassing expectations, strong cash reserves, and high margins, indicating robust scalability and efficiency. New AI-powered features and product launches enhance clinical workflows, while leadership's proven track record supports continued market expansion and service broadening.
Buy 5 High-Flying Health & Fitness Stocks of 2024 With More Upside
Five Health & Fitness stocks have strong growth potential for 2025. These are GRMN, SFM, DOCS, PLNT and PTON.
Doximity initiated with a Neutral at Mizuho
Mizuho initiated coverage of Doximity with a Neutral rating and $55 price target. The company has witnessed some volatility in quarterly top-line growth over the past few years due to timing of pharma digital ad spending within the Doximity physician user app, including decelerating top-line growth throughout much of FY24, the analyst tells investors in a research note. Mizuho adds that it remains confident in Doximity's ability to generate low double-digit annual revenue growth over the next few years, but also believes that there may be better entry points into the stock.
Are Medical Stocks Lagging Doximity (DOCS) This Year?
Here is how Doximity (DOCS) and AxoGen (AXGN) have performed compared to their sector so far this year.
Dr Martens redemption arc will be ‘multi-year event'
The post-IPO narrative surrounding footwear icon Dr Martens PLC (LSE:DOCS) has been so overwhelmingly negative that it's easy to glance over the green shoots of optimism emerging from the business. While plummeting revenues in the first half filtered through to a pre-tax loss, analysts from broker Peel Hunt noted that the numbers were broadly in line with forecasts.
Dr Martens shares booted higher despite swinging to a loss
Dr Martens PLC (LSE:DOCS)'s double-digit revenue decline and pre-tax loss in the first half wasn't as bad as it seems, if the market's reaction is anything to go by. Shares in the shoe brand, which has struggled to grow its US sales volumes, added more than 12% following publication of the results.
Dr Martens delivers double-digit sales decline and jumbo pre-tax loss
Dr Martens PLC (LSE:DOCS) had another unflattering trading performance in the first half of its financial year, with revenues declining 18% year-on-year to £325 million, in line with expectations. The iconic footwear group saw £29 million in losses before tax compared to last year's £26 million profit.
Dr Martens set to unveil loss as all eyes on outlook in results
Dr Martens PLC (LSE:DOCS)'s first half results on Thursday, 28 November will likely be more about its outlook as a decline in sales and swing to loss are expected. According to Deutsche Bank analysts, revenue is set to have fallen by 18% over the first half, pushing the shoemaker to a “well-flagged” pre-tax loss of £34 million.
3 Momentum Anomaly Stocks to Buy as Election Rally Fizzles
DOCS, PI and INOD are currently witnessing a short-term pullback in price. So, make sure you take full advantage of it.
